IBX

0.00%

4.0¢ imagion biosystems limited

Ann: First-in-human study update - First patient enrolled, page-127

First 127 Last

Share
Profile

Follow
Th3Flash

784 Posts.

370

18/06/21

19:14

Post #: 53933849
Share

Originally posted by DoubleDown!: ↑

We know that with IBX no news means no progress. Getting patient 1 took six months and while I would guess that's the hardest patient to get it's pretty clear the recruitment will be slow. Two enrollments a month is all you can expect from here.

The trial will be very lucky to finish this year with reports on the full cohort probably likely to drop in Q1 2022.

There is around 2 years of cash in the bank, though a larger trial in the second half of next year will be expensive and I expect another raise in the first half next year.

Bob has his directors fee increase, no AGM for nearly a year so there isn't much incentive for him to skip along at a decent pace. He will just bumble along with delays expected, a tiger doesn't change his stripes. He's learning as he's going and the board don't seem very good at framing a trial or hiring the right consultants to design a successful trial either. The next larger trial will be bungled just as badly and I don't think you could expect results until 2023.

If you're hanging around hoping for results to drop on an interim number of patients you might be fortunate and get something in Q4 this year.

Of course this is all guesswork on my behalf, based on watching this company for the last few years.

Expand

You should have put "this is all guess work" as your first sentence.

Bob got a small renumeration increase, yes, but anyone who finished grade 6 maths can clearly see his biggest incentive is multiplying the value of his shareholding.

IBX Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BUX

Buxton projects new graphite province discovery at WA Narryer play

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 403 more messages in this thread...

First 127 Last

Add IBX (ASX) to my watchlist

(20min delay)
Last 4.0¢		Change 0.000(0.00%)		Mkt cap ! $1.425M

Open	High	Low	Value	Volume
4.0¢	4.0¢	3.6¢	$27.63K	750.1K

Buyers (Bids)

No.	Vol.	Price($)
2	63865	3.7¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	25000	1

View Market Depth

No.	Vol.	Price($)
2	63865	0.037
1	28571	0.035
1	20000	0.034
2	48750	0.033
1	92000	0.032

Price($)	Vol.	No.
0.046	90637	1
0.047	14800	1
0.048	13016	2
0.050	105885	2
0.055	88714	1

Last trade - 13.05pm 04/10/2024 (20 minute delay)

IBX (ASX) Chart

Ann: First-in-human study update - First patient enrolled, page-127

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: First-in-human study update - First patient enrolled, page-127

Top Stories

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News